神州細胞(688520.SH):創新藥海外對外授權是公司既定的發展策略之一
格隆匯6月12日丨神州細胞(688520.SH)在互動平臺表示,SCTB14目前正在開展泛瘤種的I/II期臨牀研究,並已啓動該產品聯合化療針對NSCLC(非小細胞肺癌)的II/III期臨牀研究。SCTB41產品爲公司以差異化競爭優勢爲目標自主研發的多種實體瘤免疫治療三特異性抗體注射液,該產品目前已啓動I期臨牀研究。創新藥海外對外授權是公司既定的發展策略之一,公司將基於產品的臨牀數據,尋求產品對外授權的機會,但不確定性較大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.